Overview

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Columbia University
Duke University
University of Chicago
Treatments:
Bevacizumab
Cisplatin
Pemetrexed